aTyr Pharma, Inc.
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | 100.0% | – | – | 100.0% | – | 100.0% | – | – | – | – | – | 100.0% | – | – | – | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | 44.8% | – | – | – | – | – | – | – | – | – | – | 6.7% | – | – | 281.3% | – | 327.7% | – | – | – | – | – | 11,647.4% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | 93.3% | – | – | -181.3% | – | 100.0% | – | – | – | – | – | -11,547.4% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 3,525.5% | 2,064.7% | 2,493.1% | 44.8% | 2,307.4% | 3,118.9% | 228.8% | – | – | – | – | – | – | – | 143.6% | – | – | 2,923.2% | – | 5,686.8% | – | – | – | – | – | 11,647.4% | – | – | – | 24,782.1% | |
| – | – | – | – | – | – | – | – | – | – | – | 2,575.5% | 1,023.4% | 1,747.2% | 32.1% | 1,135.4% | 1,381.1% | 111.8% | – | – | – | – | – | – | – | 33.0% | – | – | 750.4% | – | 1,492.3% | – | – | – | – | – | 2,528.9% | – | – | – | 8,927.4% | |
| – | – | – | – | – | – | – | – | – | – | – | 6,101.1% | 3,088.0% | 4,240.3% | 76.9% | 3,442.9% | 4,500.0% | 340.6% | – | – | – | – | – | – | – | 169.8% | – | – | 3,392.4% | – | 7,179.1% | – | – | – | – | – | 2,528.9% | – | – | – | 21,854.7% | |
| – | – | – | – | – | – | – | – | – | – | – | -6,001.1% | -2,988.0% | -4,140.3% | 23.1% | -3,342.9% | -4,400.0% | -240.6% | – | – | – | – | – | – | – | -76.5% | – | – | -3,573.7% | – | -7,079.1% | – | – | – | – | – | -14,076.3% | – | – | – | -33,609.5% | |
| – | – | – | – | – | – | – | – | – | – | – | -6,221.3% | -3,067.9% | -4,259.0% | 21.7% | -3,411.1% | -4,459.5% | -240.4% | – | – | – | – | – | – | – | -72.4% | – | – | -3,213.0% | – | -6,590.2% | – | – | – | – | – | -13,550.5% | – | – | – | -32,005.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | – | – | -0.6% | – | 1.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -6,221.3% | -3,067.9% | -4,147.9% | 21.7% | -3,410.6% | -4,458.8% | -240.2% | – | – | – | – | – | – | – | -72.4% | – | – | -3,212.5% | – | -6,591.9% | – | – | – | – | – | -13,549.5% | – | – | – | -32,003.7% | |
| – | – | – | – | – | – | – | – | – | – | – | -5,642.6% | -2,802.7% | -3,895.8% | 27.5% | -3,151.3% | -4,197.3% | -228.6% | – | – | – | – | – | – | – | -65.7% | – | – | -2,931.7% | – | -6,262.6% | – | – | – | – | – | -13,463.7% | – | – | – | -30,812.6% |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.